Progressive familial intrahepatic cholestasis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 11:27:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Progressive familial intrahepatic cholestasis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Safety and Effects of Maralixibat for Patients with Alagille Syndrome https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effects-of-maralixibat-for-patients-with-alagille-syndrome/ Wed, 29 Apr 2026 15:04:39 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-and-effects-of-maralixibat-for-patients-with-alagille-syndrome/ This clinical trial is focused on studying Alagille syndrome, a rare genetic disorder that affects the liver and other parts of the body. The study will use a treatment called Livmarli, which is an oral solution containing the active substance maralixibat. The purpose of the study is to evaluate how well patients tolerate the treatment, its long-term safety, and its effectiveness in managing symptoms of Alagille syndrome.

Participants in the study will take Livmarli as prescribed, and researchers will monitor them over an extended period. The study will look at various aspects, such as any side effects experienced, changes in liver function, and the severity of itching, which is a common symptom of the disease. The study will also observe how the treatment affects the levels of certain substances in the blood and the use of other medications for liver disease.

The trial aims to gather information on the safety of Livmarli over a long period, including any potential liver-related issues. It will also assess how well patients can tolerate the starting dose and any changes in dosage. The study will continue until 2035, providing valuable insights into the long-term management of Alagille syndrome with Livmarli.

]]>